•  Net sales amounted to TSEK 1,571 (2,046).
•  The loss after tax amounted to TSEK 10,298 (11,746).
•  The loss per share amounted to SEK 0.62 (1.42).
•  The cash flow from current operations was negative in the amount of TSEK 10,119 (11,044).
•  The gross margin was 58.2% (34.2%).
•  Electrode sales in volume decreased by 18% and reached 4,304 (5,232) units. Repeat sales of electrodes decreased by 7%.

•  Net sales amounted to TSEK 3,510 (3,801).
•  The loss after tax amounted to TSEK 19,955 (23,358). The loss per share amounted to SEK 1.20 (2.82).
•  The cash flow from current operations was negative in the amount of TSEK 19,801 (23,025). 
•  The gross margin was 51.7% (30.6%).
•  Electrode sales in volume decreased by 10% and reached 8,438 (9,328) units. Repeat sales of electrodes increased by 5%.

•  In the period SciBase presented major improvements to Nevisense. The key improvement is the elimination of the need for a reference measurement, which up until now has been the most complex part of the Nevisense test. Removing this streamlines the measurement procedure and makes Nevisense straightforward to learn and use. This is a very important improvement in usability and makes the product much easier to integrate into the patient flow at dermatology clinics. 
•  The AGM 2018 was held on May 16th, 2018 
•  The first Nevisense article by US researchers was published by Svoboda, Rigel et al. in SKIN, The journal of cutaneous medicine

•  The FOBI meeting in Munich in July was the first meeting where the improved Nevisense was presented. Prof Axel Hauschild presented Nevisense in a workshop with nearly 100 attendees.

July 1
2017 -
Apr1 Jan 1 June 30 Jan 1 - Dec 31
- June - June 2018
30 30
THE GROUP 2018 2017 2018 2017 Rolling 2017
-12
Net sales, SEK ths 1 571 2 046 3 510 3 801 6 568 6 859
Gross margin, % 58,2% 34,2% 51,7% 30,6% 46,8% 35,4%
Equity/Asset ratio, % 92,0% 87,2% 92,0% 87,2% 89,9% 90,5%
Net indebtness, multiple 0,09 0,15 0,09 0,15 0,11 0,11
Cash equivalents, SEK ths 85 60 85 60 85 231 110 015
231 974 231 974
Cashflow from operating -10 -11 -19 -23 -40 955 -44 180
activities, SEK ths 119 044 801 025
Earnings per share -0,62 -1,42 -1,20 -2,82 -3,09 -5,00
(before and after
dilution), SEK
Shareholder's equity per 5,76 8,38 5,76 8,38 7,80 13,63
share, SEK
Average number of shares, 16 8 285 16 8 285 10 576 8 493
000' 618 618
Number of shares at 16 8 285 16 8 285 16 618 16 618
closing of period, 000' 618 618
Share price at end of 6,45 19,08 7,45 19,08 7,45 7,80
period, SEK
Number of sold 4 304 5 232 8 438 9 328 15 814 16 704
electrodes, pieces
Average number of 20 21 20 22 20 21
employees

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 21, 2018.

This interim report has not been subject to review by the Company's auditors. 

Contact person:

Michael Colérus, CFO

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed a unique point-of-care device for the accurate detection of malignant melanoma. Its product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and now also a FDA clearance in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies. SciBase is listed on Nasdaq First North ("SCIB"). Avanza is the certified advisor. Further information is available on www.scibase.com.